Marco Cecchi
10 Papers
18 Citations
Marco Cecchi is an academic researcher. The author has contributed to research in topics: Electroencephalography & Mini–Mental State Examination. The author has an hindex of 3, co-authored 10 publications.
Chat about Author
Papers
A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings
Marco Cecchi,Dennis Moore,Carl H. Sadowsky,Paul R. Solomon,P. Murali Doraiswamy,Charles D. Smith,Gregory A. Jicha,Andrew E. Budson,Steven E. Arnold,Kalford C. Fadem +9 more
TL;DR: This research investigates whether event‐related potentials (ERP) collected in outpatient settings and analyzed with standardized methods can provide a sensitive and reliable measure of the cognitive deficits associated with early Alzheimer's disease.
Towards automated electroencephalography-based Alzheimer's disease diagnosis using portable low-density devices
TL;DR: An automated EEG-based AD diagnosis system based on AAR and a low-density (7-channel) EEG setup is proposed and common EEG features, spectral power and coherence, are computed along with the recently proposed amplitude-modulation features.
70
Multimodal Prediction of Alzheimer's Disease Severity Level Based on Resting-State EEG and Structural MRI.
TL;DR: In this paper, the authors explored the multimodal prediction of Mini-Mental State Examination (MMSE) scores using resting-state electroencephalography (EEG) and structural magnetic resonance imaging (MRI) scans.
New exploratory Alzheimer’s drug anavex 2-73 changes in electrophysiological markers in Alzheimer’s disease: First patient data from an ongoing phase 2a study in mild-to-moderate Alzheimer’s patients
TL;DR: The maximum tolerated dose of ANAVEX2-73 is evaluated and an open-label extension for an additional 26 weeks, with daily oral dosing so as to establish a longer drug effect.
7
Safety and efficacy 31 week data of anavex 2-73 in a phase 2a study in mild-moderate alzheimer’s disease patients
Stephen Macfarlane,Marco Cecchi,Dennis Moore,Paul Maruff,Tasos Zografidis,Christopher Missling +5 more
TL;DR: P4-356 SAFETYAND EFFICACY 31 week data of Anavex 2-73 in a phase 2A study in MILDMODERATE ALZHEIMer’s disease patients is presented.
5